New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - amphotericin b 100 mg/ml - oral suspension - 100 mg/ml - active: amphotericin b 100 mg/ml excipient: glycerol

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - amphotericin b (amphotericin) -

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: hydrogenated soy phosphatidylcholine; sucrose; dl-alpha-tocopherol; distearoylphosphatidylglycerol; sodium succinate; cholesterol - indications: ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum. indicated as at 8 september 2003 :ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - amphotericin b - oral solution - 100mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amphotericin b, quantity: 10 mg - lozenge - excipient ingredients: acacia; mannitol; polyvinyl alcohol; saccharin sodium; sodium cyclamate; purified talc; stearic acid; flavour - treatment of candidal infections of the oral and perioral areas including oral thrush, angular cheilitis, denture stomatitis and in other conditions of the mouth, throat and tongue complicated by the overgrowth of candida albicans.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ciclosporin 100 mg/ml;   - oral solution - 100 mg/ml - active: ciclosporin 100 mg/ml   excipient: corn oil dl-alpha tocopherol ethanol polyethylene glycol hydrogenated castor oil propylene glycol - transplantation indications solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 100 mg/ml;   - oral solution - 100 mg/ml - active: amisulpride 100 mg/ml   excipient: caramel hydrochloric acid methyl hydroxybenzoate potassium sorbate propyl hydroxybenzoate purified water sweetener gesweet 01002023 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amphotericin b (amphotericin) -

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - ciclosporin 100 mg/ml - 100 mg/ml

United States - English - NLM (National Library of Medicine)

xgen pharmaceuticals djb, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b 50 mg in 10 ml - amphotericin b for injection usp should be administered primarily to patients with progressive, potentially life-threatening fungal infections. this potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. amphotericin b for injection usp is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), north american blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera absidia , mucor and rhizopus , and infections due to related susceptible species of conidiobolus and basidiobolus , and sporotrichosis. amphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. this product is contraindicated in those patients who have shown hypersensitivity to amphote